UBS Group’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $147K | Buy |
21,087
+11,503
| +120% | +$89.3K | ﹤0.01% | 6800 |
|
|
2025
Q4 | $67.7K | Sell |
9,584
-13,378
| -58% | -$103K | ﹤0.01% | 7082 |
|
|
2025
Q3 | $171K | Buy |
22,962
+14,323
| +166% | +$109K | ﹤0.01% | 6761 |
|
|
2025
Q2 | $63.5K | Sell |
8,639
-15,667
| -64% | -$137K | ﹤0.01% | 7582 |
|
|
2025
Q1 | $188K | Sell |
24,306
-32,778
| -57% | -$359K | ﹤0.01% | 6601 |
|
|
2024
Q4 | $691K | Buy |
57,084
+53,441
| +1,467% | +$684K | ﹤0.01% | 5616 |
|
|
2024
Q3 | $45.7K | Buy |
3,643
+1,520
| +72% | +$19.6K | ﹤0.01% | 6880 |
|
|
2024
Q2 | $25.3K | Buy |
+2,123
| New | +$29.1K | ﹤0.01% | 7151 |
|
|
2024
Q1 | – | Sell |
-333
| Closed | -$8.55K | – | 9600 |
|
|
2023
Q4 | $8.55K | Sell |
333
-6
| -2% | -$85 | ﹤0.01% | 7542 |
|
|
2023
Q3 | $2.45K | Sell |
339
-1,393
| -80% | -$9.33K | ﹤0.01% | 7702 |
|
|
2023
Q2 | $9.15K | Buy |
+1,732
| New | +$6.21K | ﹤0.01% | 7192 |
|
|
2022
Q3 | – | Sell |
-1,024
| Closed | -$14K | – | 10568 |
|
|
2022
Q2 | $14K | Buy |
+1,024
| New | +$6.81K | ﹤0.01% | 7399 |
|
|
2022
Q1 | – | Sell |
-694
| Closed | -$5K | – | 10503 |
|
|
2021
Q4 | $5K | Buy |
+694
| New | +$11.9K | ﹤0.01% | 9394 |
|
|
2021
Q3 | – | Sell |
-348
| Closed | -$11K | – | 9755 |
|
|
2021
Q2 | $11K | Sell |
348
-724
| -68% | -$24.8K | ﹤0.01% | 7965 |
|
|
2021
Q1 | $41K | Buy |
1,072
+289
| +37% | +$13.2K | ﹤0.01% | 6743 |
|
|
2020
Q4 | $37K | Buy |
783
+711
| +988% | +$30.8K | ﹤0.01% | 6454 |
|
|
2020
Q3 | $2K | Sell |
72
-21,350
| -100% | -$836K | ﹤0.01% | 7658 |
|
|
2020
Q2 | $944K | Buy |
21,422
+21,277
| +14,674% | +$999K | ﹤0.01% | 3557 |
|
|
2020
Q1 | $4K | Sell |
145
-365
| -72% | -$16.8K | ﹤0.01% | 7388 |
|
|
2019
Q4 | $26K | Buy |
510
+280
| +122% | +$11.7K | ﹤0.01% | 6728 |
|
|
2019
Q3 | $8K | Buy |
230
+215
| +1,433% | +$11.6K | ﹤0.01% | 7275 |
|
|
2019
Q2 | $1K | Sell |
15
-316
| -95% | -$19.8K | ﹤0.01% | 7714 |
|
|
2019
Q1 | $20K | Sell |
331
-981
| -75% | -$63K | ﹤0.01% | 6304 |
|
|
2018
Q4 | $78K | Buy |
1,312
+173
| +15% | +$12.8K | ﹤0.01% | 5749 |
|
|
2018
Q3 | $92K | Buy |
1,139
+248
| +28% | +$19.7K | ﹤0.01% | 5660 |
|
|
2018
Q2 | $78K | Buy |
891
+717
| +412% | +$126K | ﹤0.01% | 5629 |
|
|
2018
Q1 | $34K | Sell |
174
-3,126
| -95% | -$583K | ﹤0.01% | 5996 |
|
|
2017
Q4 | $338K | Buy |
3,300
+54
| +2% | +$2.75K | ﹤0.01% | 4566 |
|
|
2017
Q3 | $123K | Sell |
3,246
-243
| -7% | -$7.28K | ﹤0.01% | 5182 |
|
|
2017
Q2 | $122K | Buy |
3,489
+243
| +7% | +$8.72K | ﹤0.01% | 5044 |
|
|
2017
Q1 | $230K | Sell |
3,246
-78
| -2% | -$4.55K | ﹤0.01% | 4570 |
|
|
2016
Q4 | $243K | Buy |
3,324
+180
| +6% | +$16.2K | ﹤0.01% | 4657 |
|
|
2016
Q3 | $428K | Hold |
3,144
| – | – | ﹤0.01% | 4022 |
|
|
2016
Q2 | $538K | Sell |
3,144
-1
| -0% | -$171 | ﹤0.01% | 3826 |
|
|
2016
Q1 | $594K | Sell |
3,145
-38
| -1% | -$9.16K | ﹤0.01% | 3643 |
|
|
2015
Q4 | $1.12M | Buy |
+3,183
| New | +$1.25M | ﹤0.01% | 3321 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
UBS Group's GYRE Position: Q1 2026 in Review
UBS Group increased its Gyre Therapeutics (GYRE) stake by 120% in Q1 2026, buying an estimated $89.3K and bringing the position to 21,087 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #6800.
UBS Group first reported a position in GYRE in Q4 2015 and has held it in 36 quarters since. The position peaked at $1.12M in Q4 2015. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- UBS Group held 21,087 shares of Gyre Therapeutics worth $147K as of Q1 2026.
- UBS Group bought 11,503 Gyre Therapeutics shares in Q1 2026, an estimated $89.3K.
- Gyre Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6800 holding.
- UBS Group first reported a position in Gyre Therapeutics in Q4 2015 and has held it in 36 quarters since.
- UBS Group's Gyre Therapeutics position peaked at $1.12M in Q4 2015.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.